Why Is PULSE BIOSCIENCES IN (PLSE) Stock Down Today?

Why PLSE stock is down today

PLSE stock fell 10.13% to $49.61 in a sharp intraday decline driven by the company's recent SEC filings. The stock's movement followed the filing of a Form 8-K disclosing the entry into and subsequent termination of a material definitive agreement. The disclosures triggered immediate selling pressure, as investors assessed the implications of the terminated deal.

What Happened

On September 15, 2026, Pulse Biosciences filed a Form 8-K with the SEC. The filing included three items: the entry into a material definitive agreement, the termination of that same agreement, and the submission of related financial statements and exhibits. The timing and nature of the filing raised uncertainty among investors. The stock initially dropped 6.2% in the session, then continued to fall further to a 10.6% decline by the end of the next trading period. The COO, Liane Rae Teplitsky, had made two separate purchases in late August, signaling confidence in the company's direction. However, the recent developments appear to have overshadowed that optimism.

What The Data Shows

PLSE has a market cap of $3.9 billion and remains unprofitable, with an EPS of -1.18 for the trailing twelve months. The stock has a beta of 1.62, indicating higher volatility than the broader market. Over the past 52 weeks, the stock has traded between $12.56 and $58.90. On September 16, the stock printed one fresh 52-week low and two fresh 52-week highs. Short-term sentiment has deteriorated, with the 30-day average at 54 out of 100 and the 7-day average at 50. Retail traders on r/wallstreetbets are calling the stock oversold, but no actionable price targets or consensus have emerged from that chatter.

What To Watch

Investors should monitor the company's next earnings report if one is scheduled. In the absence of an announced date, coverage breadth and further developments from the recent agreement will be key to understanding the stock's next move.